Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02393703 · ClinicalTrials.gov registry record
Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer
A clinical trial of Pancreatic Cancer and Benign Pancreatic Disease, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- 181
- Enrollment target
- 1
- Study location
NCT02393703 is a study of Pancreatic Cancer and Benign Pancreatic Disease that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 181 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02393703, a study of Pancreatic Cancer and Benign Pancreatic Disease, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- 181 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to isolate and analyze exosomes, which are tiny carriers of important proteins and nucleic acids that serve as messenger systems in the blood and tissue. Blood and tissue from patients with pancreatic cancer will be compared with blood and tissue from patients with noncancerous pancreatic disease. Including patients without cancer will allow the investigators to establish "normal" values, which currently do not exist. The investigators will then look to see whether exosome activity has a connection to disease recurrence and outcomes in patients. The results of this study will be the basis for future studies exploring this area.
Conditions Studied
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2015-03 |
| Est. Completion | 2027-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02393703
The ClinicalTrials.gov registry entry for NCT02393703 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 181 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (54% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT02393703 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02393703 about?
NCT02393703 is a clinical study titled "Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer". The purpose of this study is to isolate and analyze exosomes, which are tiny carriers of important proteins and nucleic acids that serve as messenger systems in the blood and tissue. Blood and tissue from patients with pancreatic cancer will be compared with blood and tissue from patients with nonca...
What is the current status of trial NCT02393703?
This trial is currently recruiting. The enrollment target is 181 participants. The study started on 2015-03. Estimated completion is 2027-03.
What conditions does trial NCT02393703 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Benign Pancreatic Disease.
Who is sponsoring clinical trial NCT02393703?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02393703 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.